Mehmet Ali Nahit Sendur

Prof. Dr. Mehmet Ali Nahit Şendur, Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi, Ankara Şehir Hastanesi, İç Hastalıkları ve Medikal Onkoloji Uzmanı

[Yüksel Ürün @DrYukselUrun]

The best science is not only presented.
It is made reachable, safe, and centered on patients.

Grateful to ASCO organizers, staff, patients, advocates, and researchers for moving cancer care forward.

Access, safety, and patient-centered care must remain our compass.

#ASCO26 @ASCO @ASCOPres @OncoAlert @OpenMedicineHQ @AmandaBinDC @ConquerCancerFd

[Yüksel Ürün @DrYukselUrun]

KRAS is no longer undruggable!!!
Pancreatic cancer. 5-year survival under 15%. No targeted therapy for decades. One oral pill just nearly doubled survival in a Phase 3 trial. @OncoAlert

[Yüksel Ürün @DrYukselUrun]

Ask every patient about complementary and alternative medicine (CAM) not to judge, but to protect!
Use of CAM instead of traditional therapies associated with a reduction in survival in breast cancer!
@JAMANetworkOpen @OncoAlert @BreastCancerNow

[Yüksel Ürün @DrYukselUrun]

In patients with stage III dMMR colon cancer:
Adding atezolizumab to mFOLFOX6 significantly improved 3-year disease-free survival (86%🆚76%).
Immunotherapy continues to reshape our approach.
@NEJM @OncoAlert @ONCOassist

[Tom Powles @tompowles1]

sac-TMT+pembro in 1st line UC shows ⬆️⬆️ efficacy (Fudan Uni 🇨🇳) . It’s a TROP2/TOPO1 ADC but efficacy looks different from SG or D-DXD @scocmem

In 1st line UC it has 68% ORR , 1yr PFS & 80% 12 month OS. 60% TRAEs,13% tox discontinuations. This mono and combo requires further exploration. @OncoAlert

[Yüksel Ürün @DrYukselUrun]

Perioperative MIBC is entering a new era.
The question is no longer if.
It is which regimen, for which patient.
#gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

[Vumedi Oncology @VuMediHemOnc]

🎯 #IGICC | Managing biomarker-negative metastatic gastric cancer remains challenging.

Dr. Mehmet Ali Nahit Sendur @nahit_sendur reviews first-line doublet chemotherapy standards, the limited role of triplet regimens, and evolving second-line strategies including ramucirumab-based therapy and IO in later lines.

🎥 Watch on #Vumedi: https://t.co/f8wt2qcTrM

#GastricCancer #GIOncology #CancerTreatment

[Tom Powles @tompowles1]

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26

[Tom Powles @tompowles1]

KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.

[Yüksel Ürün @DrYukselUrun]

Çok önemli, tarihi bir gelişme.

Yıllarca p53 için “ilaçlar için hedeflenemez” denildi.
Kanser gelişiminde çok önemli bir gen!🧬
Belki artık bu cümleyi yeniden düşünme zamanı.

NEJM’de yayımlanan faz 1 çalışmada,TP53 Y220C mutasyonunu hedefleyen rezatapopt ile ümit veren sonuçlar.

Henüz bir dönüm noktası değil.

Ama şunu gösteriyor:
Doğru biyolojiyi anladığımızda,
“imkânsız” dediğimiz kapılar aralanabiliyor.
@NEJM

[Yüksel Ürün @DrYukselUrun]

Erkeklerde kanserlerin %45’i,
Kadınlarda %30’u önlenebilir.
@saglikbakanligi @WHO_Turkiye @WHO @DrTedros #WorldCancerDay

[Yüksel Ürün @DrYukselUrun]

Farelerde kanseri iyileştirmek her hafta manşet olan akademik bir başarıdır, ancak insanın biyolojik labirentinde bu başarıların %90'ı sessizce kaybolur. Barbacid’in talep ettiği 30 milyon €, bir ilacın gerçek dünyaya ulaşması için gereken milyon dolarlık okyanusta sadece küçük bir damladır.

Pazarlama🆚Bilim arasındaki gerilim, onkoloji dünyasında sadece bir iletişim sorunu değil, aynı zamanda etik bir yol ayrımıdır. Bilim, doğası gereği şüpheci ve sabırlıdır; her yeni veriyi en sert testlerden geçirerek doğrulamaya odaklanır. Pazarlama ise bu sürecin içindeki küçük bir başarıyı alıp, onu "mucize" veya "devrim" etiketiyle bir umut ürününe dönüştürerek satışa sunar.

Bizim görevimiz insanlara sadece duymak istediklerini söylemek değil; karmaşayı sadeleştirerek, güven veren bir gerçekliğin huzurunu hissettirmektir.
#pankreas #kanser

[Yüksel Ürün @DrYukselUrun]

PATINA: Adding palbociclib to maintenance anti-HER2 + endocrine therapy improved PFS in HR+/HER2+ Met. Breats Cancser (44.3 vs 29.1 mo).
More toxicity, mainly neutropenia.
@NEJM @OncoAlert @AnnPartridgeMD @DrEricWiner @StoverLab @LoiSher @BreastCancerNow

[Yüksel Ürün @DrYukselUrun]

In mice, pairing daraxonrasib with afatinib and a STAT3 degrader erased tumors and kept them away for 200+ days, with good tolerance.
Promising and hopeful results for pancreatic cancer by Mariano Barbacid and team!
But mouse “cures” need human proof. @CNIOStopCancer @PNASNews @OncoAlert

[Oncology Brothers @OncBrothers]

This is the table we’ve used (common AEs, black📦warnings, & dose⬇️) during our ToxCheck 🗣️ on ADCs in #LungCancer with @sands_jacob:

1. TDXd: 🫁, Nausea, fatigue
2. DatoDXd: Stomatitis, dry 👀, 🫁
3. TelisoV: Neuropathy

#OncTwitter #MedTwitter #lcsm @OncoAlert @OncUpdates

[Mustafa Özdoğan, MD @ozdogan_md]

For the first time, a CDK4/6 inhibitor shows a statistically significant and clinically meaningful OS benefit in the adjuvant setting.

Adj CDK4/6 inh in HR+/HER2– early breast cancer is here to stay — but not for everyone.

Both monarchE (abemaciclib, 7-year OS benefit) and NATALEE (ribociclib, 5-year iDFS benefit) have reshaped the adjuvant landscape.

✅ monarchE: HR for OS 0.84; sustained IDFS/DRFS gains → early micrometastatic suppression with a durable carry-over effect.

✅ NATALEE: HR for iDFS 0.71; broader inclusion (N0–N+), lower dose (400 mg × 3 years), favorable tolerability.

Yet, these are not “treat-all” signals.

🔹 The absolute benefit remains modest for lower-risk or node-negative cases.
🔹 Long-term toxicity, adherence, and cost-effectiveness data will define real-world value.

Bottom line: Adj CDK4/6 inhibition should be selective, not universal — guided by pathological risk, biology, and patient preference.

#ESMO25 #BreastCancer #Abemaciclib #monarchE #CDK46 #Oncology #ClinicalResearch

[Tom Powles @tompowles1]

The final analysis of cabozantinib plus nivolumab in 1st line clear cell renal cancer @Annals_Oncology @DrChoueiri shows consistent data over time and with other VEGF/PD-1 combinations. ‘Pick one and use it well’ remains a good approach.

[OncoAlert @OncoAlert]

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

https://t.co/EAuOTguOuF

This phase 3 trial evaluating first-line treatment for HER2-positive advanced or metastatic #BreastCancer , trastuzumab deruxtecan plus pertuzumab significantly improved outcomes compared with the standard regimen of a taxane, trastuzumab, and pertuzumab (THP). Among previously untreated patients, median progression-free survival was 40.7 months with trastuzumab deruxtecan plus pertuzumab versus 26.9 months with THP (hazard ratio, 0.56; P<0.00001), and confirmed responses were more frequent and durable (85.1% vs. 78.6%; median duration of response 39.2 vs. 26.4 months). Safety findings were consistent with known profiles, though interstitial lung disease or pneumonitis occurred more often with trastuzumab deruxtecan (12.1% vs. 1.0%).

Overall, the combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns, supporting its potential as a new first-line standard for HER2-positive metastatic breast cancer.

@stolaney1
@DrRBarroso
@mfrimawi
@ToiMasakazu
@nahit_sendur
@mlcasalnuovo
@LoiblSibylle

@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @jesusanampa @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @MammaMiaMagazin

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88

[Oncology Brothers @OncBrothers]

9 Breast Ca studies that we touched on with @VKaklamani for #ESMO25:

✅ #monarchE &amp; #NATALEE
✅ #VIKTORIA1
✅ #evERA
✅ #DESTINYBreast: 05/09/11
✅ #ASCENT03
✅ #TropionBreast02

#OncTwitter #MedTwitter @OncUpdates @myESMO @OncoAlert

[Yüksel Ürün @DrYukselUrun]

Disitamab vedotin + toripalimab doubles survival benefit vs chemo in HER2+ urothelial carcinoma.
Median OS: 31.5 vs 16.9 mo (HR 0.54).

@TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle @Ecastromarcos @GillSharlene @PGrivasMDPhD @ErikaHamilton9 @DrAngelaLamarca @DrJonLim @StephenVLiu @LoiSher @DrJNaidoo @NReguart @LorenzaRimassa @Rodrosb @LizzySmyth1 @pawel_sobczuk @PTarantinoMD @darioT_ @ArndtVogel @TiansterZhang
#ESMOAmbassadors #ESMO25
@neerajaiims @yekeduz_emre @tompowles1 @OncoAlert @ONCOassist @OncBrothers @dmukherji @curijoey @DrChoueiri